Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 19, 2018 - Issue 3-4
Submit an article Journal homepage
2,849
Views
20
CrossRef citations to date
0
Altmetric
Research Article

VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics

Jinsy A. Andrews1 Eleanor and Lou Gehrig ALS Center, Columbia University, New York, NY, USA,
,
Merit E. Cudkowicz2 Department of Neurology, Massachussetts General Hospital, Boston, MA, USA,
,
Orla Hardiman3 Biomedical Sciences Institute of Neurosciences, The University of Dublin, Dublin, Ireland,
,
Lisa Meng4 Cytokinetics, Inc, South San Francisco, CA, USA, and
,
Amy Bian4 Cytokinetics, Inc, South San Francisco, CA, USA, and
,
Jacqueline Lee4 Cytokinetics, Inc, South San Francisco, CA, USA, and
,
Andrew A. Wolff4 Cytokinetics, Inc, South San Francisco, CA, USA, and
,
Fady I. Malik4 Cytokinetics, Inc, South San Francisco, CA, USA, and
&
Jeremy M. Shefner5 Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USACorrespondence[email protected]
 show all
Pages 259-266 | Received 04 Aug 2017, Accepted 19 Dec 2017, Published online: 06 Feb 2018

References

  • The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol. 2012;19:360–75.
  • Gordon PH. Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis. 2013;4:295–310.
  • Rocha JA, Reis C, Simões F, Fonseca J, Mendes Ribeiro J. Diagnostic investigation and multidisciplinary management in motor neuron disease. J Neurol. 2005;252:1435–47.
  • Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5:140–7.
  • Goyal NA, Mozaffar T. Respiratory and nutritional support in amyotrophic lateral sclerosis. Curr Treat Options Neurol. 2014;16:270.
  • Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, et al. Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 1995–2010. PLoS One. 2013;8:e74733.
  • Shefner JM, Watson ML, Meng L, Wolff AA, The Neals/Cytokinetics STUDY Team. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:574–81.
  • Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:191–206.
  • Traynor K. FDA approves edaravone for amyotrophic lateral sclerosis. Am J Health Syst Pharm. 2017;74:868.
  • Yamamoto Y. Plasma marker of tissue oxidative damage and edaravone as a scavenger drug against peroxyl radicals and peroxynitrite. J Clin Biochem Nutr. 2017;60:49–54.
  • Shefner JM. Muscle as a therapeutic target in amyotrophic lateral sclerosis. Exp Neurol. 2009;219:373–5.
  • Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, et al. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014;9:e96921.
  • Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012;18:452–5.
  • Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, et al. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2014;50:925–31.
  • Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, et al. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:426–35.
  • Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, et al. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:430–8.
  • Shefner J, Andrews J, Meng L, Bian A, Wolff AA. Relationships between riluzole and tirasemtiv levels on outcomes in the BENEFITS-ALS trial. Presented at the 25th International Symposium on ALS/MND, Brussels, Belgium.
  • Andrews JA, Wolff AA, Lee J, Barragan D, Meng L, Bian A, et al. Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices of Treatment for a Year in ALS (VITALITY-ALS): study design of a phase III clinical trial of tirasemtiv in ALS. Presented at the MDA Clinical Conference, Arlington, VA, USA.
  • Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.